$NTLA Cashflow Statement | Understand Stock

$NTLA

$12.28 +$1.02 (9.06%) Close

$NTLA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss (gain) on disposal of property and equipment
Accelerated amortization/impairment of right-of-use assets
Stock-based compensation
Accretion of investment discounts and premiums
Change in fair value of investments, net
AvenCell Member
Sparing Vision SAS
Kyverna
Total change in fair value of investments, net
(Recognition) deferral of equity method investment intra-entity profit on sales
Loss from equity method investment
AvenCell Member
Total loss from equity method investment
Deferral of equity method investment intra-entity profit on sales
Change in fair value of contingent consideration
In-process research and development expense
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Operating lease right-of-use assets
Other assets
Accounts payable
Accrued expenses
Deferred revenue
Operating lease liabilities

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment
Purchases of marketable securities
Sales and maturities of marketable securities
Proceeds from sale of property and equipment
Acquired in-process research and development, net of cash acquired of $287
Investment in Kyverna Therapeutics, Inc.
Net cash provided by (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock
At The Market Offerings
Regeneron Pharmaceuticals Inc.
Follow-on Offering
Total net proceeds from issuance of common stock

Proceeds from options exercised
Issuance of shares through employee stock purchase plan
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash equivalents
Cash, cash equivalents and restricted cash equivalents, beginning of period
Cash, cash equivalents and restricted cash equivalents, end of period
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Purchases of property and equipment unpaid at period end
Reduction of right-of-use assets from remeasurement of lease liabilities
Operating lease liabilities arising from obtaining right-of-use assets
Right-of-use assets acquired under operating leases
Non-cash trade-in of property and equipment
Non-cash contribution of intellectual property
AvenCell Member
Sparing Vision SAS
Kyverna
Proceeds from at-the-market offerings unpaid at period end
Shares issued for Rewrite contingent consideration
Contingent consideration liability assumed in asset acquisition
Reconciliation of cash, cash equivalents and restricted cash equivalents to consolidated balance sheet:
Cash and cash equivalents
Restricted cash equivalents, included in investments and other assets

Comments